NEW YORK, Oct. 9 – Myriad Genetics of Salt Lake City said Tuesday it had discovered a drug target for treating cancer using its proteomics technology.

In a statement, Myriad said that the ProNet technology allowed the company to look at protein interactions involved in apoptosis and to apply the knowledge garnered to identifying a target for cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.